AMP Survey Finds that Inadequate Reimbursement Hinders Use of Molecular Diagnostics
Inadequate reimbursement is hindering utilization of molecular testing. That is the conclusion of a new survey from the Association of Molecular Pathology (AMP). Survey respondents also suggested that providing adequate reimbursement for molecular testing would improve not only patient access to but also the quality of medical care by enabling more data-driven treatment decisions. The Diagnostic Challenge Molecular diagnostics is a field of laboratory medicine that analyzes human genes to gain a better understanding of diseases, how they develop and how best to treat them. In addition to enabling earlier and more accurate detection of disease, data provided by molecular diagnostics plays a key role in personalized medicine. Today, clinical laboratories of all sizes and settings provide molecular diagnostics services, typically via both physicians and qualified doctoral scientists with specialized training and experience. Typically, it requires extensive analysis, interpretation and reporting—often more than six hours per test, according to the AMP survey. That is a considerable investment in time, expertise and professional effort. However, many believe that reimbursement provided by current payment systems is not nearly commensurate with the value of these services. The AMP Survey Published on March 16, the AMP survey “Analysis of Professional Work Effort in Molecular […]
- Increasing utilization in complex testing paradigms, such as whole genome sequencing, whole exome sequencing and next generation sequencing will likely result in higher analysis, interpretation, and reporting burdens in the future;
- Laboratories are using more non-doctorate case managers for communication, limiting the number of tests offered, and sending out tests to manage costs;
- Current trends and limited reimbursement may compel community laboratories to stop performing molecular tests which would then be redirected to academic and national reference laboratories; and
- Academic and large laboratories could be stressed by an influx of poorly reimbursed tests that other laboratories no longer perform.
Subscribe to Clinical Diagnostics Insider to view
Start a Free Trial for immediate access to this article